Literature DB >> 26366382

Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer.

Hwa Yeon Yang1, Sung Chan Park1, Jong Hee Hyun1, Ho Kyung Seo2, Jae Hwan Oh1.   

Abstract

PURPOSE: The objective of this study was to assess the clinical outcomes of pelvic exenteration for patients with primary locally advanced colorectal cancer (LACRC) or locally recurrent colorectal cancer (LRCRC), and to identify clinically relevant prognostic factors.
METHODS: Between January 2001 and December 2010, 40 consecutive patients with primary LACRC or LRCRC underwent pelvic exenteration at the National Cancer Center, Republic of Korea. We retrospectively reviewed their medical records.
RESULTS: The median age was 59 years and the median follow-up time was 26 months (range, 1-117 months). The overall complication and in-hospital mortality rates were 70% (28/40) and 7.5% (3/40), respectively. The complication rates were similar between patients with primary LACRC (69.6%) and those with LRCRC (70.6%). The overall recurrence rate was 50% (17/34), and was lower in patients with primary LACRC than in patients with LRCRC (33.3% vs. 76.9%, P = 0.032). The 5-year overall survival was significantly different between primary LACRC and patients with LRCRC (58.7% vs. 11.8%, P = 0.022). Multivariate analysis revealed that radicality (R0 vs. R1/R2) was an independent prognostic factor for overall survival (P = 0.020).
CONCLUSION: The complication and operative mortality rates of pelvic exenteration remained high, but pelvic exenteration might provide an opportunity for long-term survival and good local control. Complete (R0) resection was the only independent prognostic factor for overall survival.

Entities:  

Keywords:  Colorectal neoplasms; Local neoplasm recurrences; Pelvic exenteration

Year:  2015        PMID: 26366382      PMCID: PMC4559615          DOI: 10.4174/astr.2015.89.3.131

Source DB:  PubMed          Journal:  Ann Surg Treat Res        ISSN: 2288-6575            Impact factor:   1.859


  19 in total

1.  Total pelvic exenteration for rectal cancer: outcomes and prognostic factors.

Authors:  Trustin S Domes; Patrick H D Colquhoun; Brian Taylor; Jonathan I Izawa; Andrew A House; Patrick P W Luke; Jonathan I Izawa
Journal:  Can J Surg       Date:  2011-12       Impact factor: 2.089

2.  Outcome of total pelvic exenteration for locally recurrent rectal cancer.

Authors:  Hideyuki Ike; Hiroshi Shimada; Shigeo Ohki; Shigeki Yamaguchi; Yasushi Ichikawa; Shouichi Fujii
Journal:  Hepatogastroenterology       Date:  2003 May-Jun

3.  Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?

Authors:  Nuh N Rahbari; Alexis B Ulrich; Thomas Bruckner; Marc Münter; Axel Nickles; Pietro Contin; Thorsten Löffler; Christoph Reissfelder; Moritz Koch; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

4.  Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy.

Authors:  A BRUNSCHWIG
Journal:  Cancer       Date:  1948-07       Impact factor: 6.860

5.  Local involvement of the urinary bladder in primary colorectal cancer: outcome with en-bloc resection.

Authors:  D C Winter; R Walsh; G Lee; D Kiely; M G O'Riordain; G C O'Sullivan
Journal:  Ann Surg Oncol       Date:  2006-10-25       Impact factor: 5.344

6.  Outcomes of total pelvic exenteration for colorectal cancer.

Authors:  Minoru Nishio; Chohei Sakakura; Tomoyuki Nagata; Atsushi Miyashita; Takuo Hamada; Hisashi Ikoma; Takeshi Kubota; Masayoshi Nakanishi; Akio Kimura; Daisuke Ichikawa; Syoujirou Kikuchi; Hitoshi Fujiwara; Kazuma Okamoto; Toshiya Ochiai; Yukihito Kokuba; Hiroki Taniguchi; Teruhisa Sonoyama; Akeo Hagiwara; Eigo Otsuji
Journal:  Hepatogastroenterology       Date:  2009 Nov-Dec

7.  Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma.

Authors:  Christopher J Gannon; Jonathan S Zager; George J Chang; Barry W Feig; Christopher G Wood; John M Skibber; Miguel A Rodriguez-Bigas
Journal:  Ann Surg Oncol       Date:  2007-04-04       Impact factor: 5.344

8.  Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period.

Authors:  Seiji Ishiguro; Takayuki Akasu; Shin Fujita; Seiichiro Yamamoto; Miranda Kusters; Yoshihiro Moriya
Journal:  Surgery       Date:  2008-12-23       Impact factor: 3.982

9.  Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer.

Authors:  Joo Ho Lee; Dae Yong Kim; Sun Young Kim; Ji Won Park; Hyo Seong Choi; Jae Hwan Oh; Hee Jin Chang; Tae Hyun Kim; Suk Won Park
Journal:  Radiat Oncol       Date:  2011-05-20       Impact factor: 3.481

10.  Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution.

Authors:  Horacio N López-Basave; Flavia Morales-Vásquez; Angel Herrera-Gómez; Alejandro Padilla Rosciano; Abelardo Meneses-García; Juan M Ruiz-Molina
Journal:  Cancer Manag Res       Date:  2012-10-11       Impact factor: 3.989

View more
  3 in total

1.  Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer.

Authors:  E Platt; G Dovell; S Smolarek
Journal:  Tech Coloproctol       Date:  2018-12-01       Impact factor: 3.781

2.  Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness.

Authors:  Melanie Lindenberg; Astrid Kramer; Esther Kok; Valesca Retèl; Geerard Beets; Theo Ruers; Wim van Harten
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

3.  Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach.

Authors:  Tetsuro Tominaga; Takashi Nonaka; Akiko Fukuda; Toshio Shiraisi; Shintaro Hashimoto; Masato Araki; Yorihisa Sumida; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Ann Surg Treat Res       Date:  2021-07-29       Impact factor: 1.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.